Company Category: Drug Discovery
Next-Gen Immuno-oncology and Immunological TherapeuticsDetails
Harbour BioMed is a multinational clinical stage biopharmaceutical company developing next-gen therapeutics in the areas of immuno-oncology and immunological diseases.
Our research and development efforts are powered by unmet medical and patient needs and solid science backed by our two proprietary transgenic mouse platforms (Harbour Mice ®) for both fully human monoclonal antibodies (H2L2) and HCAb-based immune cell engager (HBICETM) bispecific antibodies. The platforms have broad potential for generating both conventional antibody therapeutics as well as the next-gen biologics that are affinity matured, fully human with excellent solubility and development readiness.
Harbour Mice® – Generating Human Antibodies for Therapy
Most of the of fully human antibodies approved to date in the U.S. have been developed from a transgenic mice platform.
Transgenic mice are recognised as powerful tools for use in drug discovery based on their ability for producing fully human antibodies.
H2L2 mice generates traditional tetrameric antibodies comprised of two heavy chains and two light chains.
HCAb‘s technology generates new “heavy chain only” antibodies, which are around half the size of a typical IgG. These antibodies carry IgG-like PK properties and Fc-domain functions without the need for additional engineering or humanisation.
Single Cell Technology Platform
Through our collaboration with Berkeley lights with its advanced Beacon® Optofluidic technology, we established our proprietary single cell technology platform currently focusing on single B cell cloning to enhance BioMed’s fully human antibody discovery capability and single cell analysis for cancer research and translational medicine.
Harbour BioMed is focusing on developing an innovative pipeline of therapeutics through internal R&D programs, collaborations with co-discovery and co-development partners, as well as select acquisitions.
With operations in America, Europe and Asia, we also license our innovative core platform technology to other companies and academic institutions globally.Press ReleasesHarbour BioMed, a global clinical stage biopharmaceutical company developing novel therapeutics in the fields of immuno-oncology, immunologic diseases, and COVID-19, …
Read MoreAbbVie, Harbour BioMed, Utrecht University and the Erasmus Medical Center (EMC) revealed today they have entered into a partnership to …
Read MoreScientists at clinical-stage biopharmaceutical company Harbour BioMed (HBM), Utrecht University and Erasmus Medical Center announced that they have discovered a …
United States of America
Address: 1 Broadway, 14th Floor, Cambridge, MA 02142, USA
Address: CIC Rotterdam, Groothandelsgebouw, Stationsplein 45, Unit A4.004
3013 AK Rotterdam, The Netherlands
Address: 6F, No. 987 Cailun Road, Pudong New Area, Shanghai, China 201203
Address: 12F, Tower A, No. 420 Fenglin Road, Xuhui District, Shanghai, China 200032
Address: Suite 202, Building A3, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, China, 215028
Email Us at:
For General Enquires or Investor Relations
For Business Development Enquires
Send an enquiry